Increase in atrial contractility induced by PGE2 in diabetic rats

Mostrar otras versiones (1)

Contractile response to exogenous prostaglandin E2 (PGE2) was studied in auricles from normal and acutely-diabetic (streptozotocin-treated) rats. In normal atria, PGE2 induced a biphasic inotropic effect negative at low concentrations and positive at higher ones. In diabetic, PGE2 only elicited a po...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Canga, L.
Otros Autores: Sterin-Borda, L.
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 1986
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 07499caa a22011657a 4500
001 PAPER-18201
003 AR-BaUEN
005 20230518204934.0
008 190411s1986 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0022458602 
024 7 |2 cas  |a acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; dithizone, 60-10-6; indometacin, 53-86-1, 74252-25-8, 7681-54-1; nordihydroguaiaretic acid, 500-38-9; phenoxybenzamine, 59-96-1, 63-92-3; phentolamine, 50-60-2, 73-05-2; prazosin, 19216-56-9, 19237-84-4; propranolol, 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; prostaglandin E2, 363-24-6; streptozocin, 18883-66-4; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Arachidonic Acid, 506-32-1; Arachidonic Acids; Cyclooxygenase Inhibitors; Dinoprostone, 363-24-6; Lipoxygenase Inhibitors; Prostaglandins E; Thromboxane-A Synthase, EC 5.3.99.5 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a PLRCA 
100 1 |a Canga, L. 
245 1 0 |a Increase in atrial contractility induced by PGE2 in diabetic rats 
260 |c 1986 
270 1 0 |m Sterin-Borda, L.; Centro de Estudios Farmacologicos y de Principios Naturales (CEFAPRIN)-CONICET. Serrano 665/669, 1414 Buenos Aires, Argentina 
506 |2 openaire  |e Política editorial 
504 |a Borda, Peredo, Gimeno, (1983) Prostaglandins, 26, p. 701 
504 |a Borda, Sterin-Borda, Gimeno, Lazzari, Gimeno, (1983) Experientia, 39, p. 894 
504 |a Canga, Sterin-Borda, Borda, Peredo, Gimeno, (1984) Eur. J. Pharmacol., 110, p. 47 
504 |a Downing, Lee, Fripp, (1983) Am. J. Physiol., 245, p. H808 
504 |a Farah, Alousi, (1981) Life Sci., 29, p. 975 
504 |a Fischer, Yates, (1957) Statistical tables for biological, agricultural and medical research, , 5th ed., Hafner Publishing Co., New York 
504 |a Gerrard, Stuart, Rao, Steffes, Mauer, Brown, White, (1980) J. Lab. Clin. Med., 95, p. 950 
504 |a Hamberg, (1976) Biochim. Biophys. Acta, 431, p. 651 
504 |a Hamby, Zoneraich, Sherman, (1974) J. Am. Med. Ass., 229, p. 1749 
504 |a Harrison, Reece, Johnson, (1978) Life Sci., 23, p. 351 
504 |a Johnson, Reece, Harrison, (1985) Adv. Prostaglandin Thromboxane Res., 8, p. 1283 
504 |a Kannel, Hjortland, Castelli, (1974) Am. J. Cardiol., 34, p. 29 
504 |a Kannel, Mc Gee, (1979) J. Am. Med. Ass., 241, p. 2035 
504 |a Lapetina, (1982) Trends Pharmacol. Sci., 3, p. 115 
504 |a Ledet, Neubauer, Christensen, Lundback, (1979) Diabetología, 16, p. 207 
504 |a Moncada, Bunting, Mullane, Thorogood, Vane, Raz, Needleman, (1977) Prostaglandins, 13, p. 611 
504 |a Moncada, Vane, (1978) Br. Med. Bull., 34, p. 129 
504 |a Moncada, Vane, (1979) Pharmacol. Rev., 30, p. 293 
504 |a Nakashima, Tsuru, Shiggei, (1973) J. Pharmacol., 23, p. 307 
504 |a Penpargkul, Schaible, Vipintsoi, Scheuer, (1980) Circ. Res., 47, p. 911 
504 |a Piper, Samhoun, (1981) Prostaglandins, 24, p. 793 
504 |a Pistorius, Axelrod, (1974) J. Biol. Chem., 249, p. 3183 
504 |a Sterin-Borda, Borda, del Catillo, Gimeno, Gimeno, (1982) Experientia, 38, p. 835 
504 |a Sterin-Borda, Canga, Gimeno, (1981) Experientia, 37, p. 592 
504 |a Sterin-Borda, Canga, Pissani, Gimeno, (1980) Prostaglandins, 20, p. 825 
504 |a Sterin-Borda, Franchi, Borda, del Castillo, Gimeno, Gimeno, (1984) Eur. J. Pharmacol., 103, p. 211 
504 |a Vadlamudi, Vadlamudi, Rodgers, McNeill, (1982) Physiol. Pharmacol., 60, p. 902 
504 |a Vane, (1971) Nature New Biol., 231, p. 232 
504 |a Van Rossum, (1963) Arch. int. Pharmacodyn, Ther., 143, p. 299 
520 3 |a Contractile response to exogenous prostaglandin E2 (PGE2) was studied in auricles from normal and acutely-diabetic (streptozotocin-treated) rats. In normal atria, PGE2 induced a biphasic inotropic effect negative at low concentrations and positive at higher ones. In diabetic, PGE2 only elicited a positive inotropic action which was greater in efficacy and potency than in normal controls. Incubation of diabetic atrial preparations with α-adrenoceptor antagonists (phentolamine, phenoxybenzamine or Prazosin) diminished the prostaglandin effect. However, blockade of β-adrenoceptors with propranolol did not modify the response. Blockers of arachidonic acid metabolism via cyclo-oxygenase (indomethacin and acetylsalicylic acid) or via lipoxygenase(s) (nordihydroguaiaretic acid and dithizone) were able to reduce the positive inotropism of PGE2. A significant blockade of the stimulant action of PGE2 was seen in the presence of inhibitors of thromboxane synthesis (L-8027 and imidazole). These results suggest that in diabetic atria PGE2 effect could be associated to an involvement of cardiac α-adrenergic stimulation which promotes endogenous arachidonic acid release with diversification of its metabolism towards cyclo- and lipoxygenase(s)- pathway and direct to an increased thromboxane formation which could account for the positive inotropic effect induced by PGE2. © 1986.  |l eng 
593 |a Centro de Estudios Farmacologicos y de Principios Naturales (CEFAPRIN)-CONICET. Serrano 665/669, 1414 Buenos Aires, Argentina 
690 1 0 |a ACETYLSALICYLIC ACID 
690 1 0 |a ALPHA ADRENERGIC RECEPTOR 
690 1 0 |a DITHIZONE 
690 1 0 |a INDOMETACIN 
690 1 0 |a NORDIHYDROGUAIARETIC ACID 
690 1 0 |a PHENOXYBENZAMINE 
690 1 0 |a PHENTOLAMINE 
690 1 0 |a PRAZOSIN 
690 1 0 |a PROPRANOLOL 
690 1 0 |a PROSTAGLANDIN E2 
690 1 0 |a STREPTOZOCIN 
690 1 0 |a ANIMAL CELL 
690 1 0 |a ANIMAL EXPERIMENT 
690 1 0 |a ARACHIDONIC ACID METABOLISM 
690 1 0 |a DRUG EFFICACY 
690 1 0 |a ENDOCRINE SYSTEM 
690 1 0 |a HEART 
690 1 0 |a HEART ATRIUM 
690 1 0 |a HEART MUSCLE 
690 1 0 |a HEART MUSCLE CONTRACTILITY 
690 1 0 |a INTRAVENOUS DRUG ADMINISTRATION 
690 1 0 |a NONHUMAN 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a RAT 
690 1 0 |a STREPTOZOCIN DIABETES 
690 1 0 |a ADRENERGIC ALPHA-ANTAGONISTS 
690 1 0 |a ADRENERGIC BETA-ANTAGONISTS 
690 1 0 |a ANIMAL 
690 1 0 |a ARACHIDONIC ACID 
690 1 0 |a ARACHIDONIC ACIDS 
690 1 0 |a CYCLOOXYGENASE INHIBITORS 
690 1 0 |a DIABETES MELLITUS, EXPERIMENTAL 
690 1 0 |a DINOPROSTONE 
690 1 0 |a IN VITRO 
690 1 0 |a LIPOXYGENASE INHIBITORS 
690 1 0 |a MALE 
690 1 0 |a MYOCARDIAL CONTRACTION 
690 1 0 |a PROSTAGLANDINS E 
690 1 0 |a RATS 
690 1 0 |a RATS, INBRED STRAINS 
690 1 0 |a SUPPORT, NON-U.S. GOV'T 
690 1 0 |a THROMBOXANE-A SYNTHASE 
700 1 |a Sterin-Borda, L. 
773 0 |d 1986  |g v. 18  |h pp. 371-384  |k n. 4  |p Pharmacol. Res. Commun.  |x 00316989  |t Pharmacological Research Communications 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022458602&doi=10.1016%2f0031-6989%2886%2990090-1&partnerID=40&md5=f3ecf7ee4d6c7c6201825568ce420486  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1016/0031-6989(86)90090-1  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_00316989_v18_n4_p371_Canga  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00316989_v18_n4_p371_Canga  |y Registro en la Biblioteca Digital 
961 |a paper_00316989_v18_n4_p371_Canga  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 79154 

Ejemplares similares